Lipid Mediators and Human Leukemic Blasts by Fiancette, Rémi et al.
Hindawi Publishing Corporation
Journal of Oncology
Volume 2011, Article ID 389021, 7 pages
doi:10.1155/2011/389021
Review Article
LipidMediators andHuman LeukemicBlasts
R´ emi Fiancette,1 ChristelleVincent-Fabert,1 EstelleGuerin,2
Franck Trimoreau,2 andYvesDenizot1
1Centre National de la Recherche Scientiﬁque, CNRS UMR 6101, Facult´ ed eM ´ edecine, Universit´ e de Limoges,
2 rue Dr. Marcland, 87025 Limoges, France
2Laboratoire d’H´ ematologie, CHU Dupuytren, 87042 Limoges, France
Correspondence should be addressed to Yves Denizot, yves.denizot@unilim.fr
Received 16 June 2010; Revised 23 September 2010; Accepted 24 September 2010
Academic Editor: Aurelio Lorico
Copyright © 2011 R´ emi Fiancette et al.ThisisanopenaccessarticledistributedundertheCreativeCommonsAttributionLicense,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Someofthemostpotentinﬂammatorymediatorssharealipidorigin.Theyregulateawidespectrumofcellularprocessesincluding
cell proliferation and apoptosis. However, the precise roles and ways (if any) in which these compounds impact the growth
and apoptosis of leukemic blasts remain incompletely resolved. In spite of this, signiﬁcant advances have been recently made.
Here we brieﬂy review the current knowledge about the production of lipid mediators (prostaglandins, leukotrienes, platelet-
activating factor) by leukemic blasts, the enzymatic activities (phospholipase A2, cyclooxygenases, lipoxygenases) involved in their
productions and their eﬀects (through speciﬁc membrane bound receptors) on the growth, and apoptosis of leukemic blasts.
1.Introduction
Some of the most potent inﬂammatory mediators share a
lipid origin. The action of phospholipase A2 (PLA2)o n
membrane phospholipids produces free fatty acids such as
arachidonic acid (AA) and the phospholipid backbone. To
the former belongs eicosanoids (such as prostaglandins,
prostacyclin, thromboxane, and leukotrienes) through the
cyclooxygenase (COX) and lipoxygenase (LOX) pathways;
and to the latter, platelet-activating factor (PAF) (Figure 1)
[1,2].Whilecountlessstudieshavehighlightedtheactionsof
eicosanoids and PAF on normal human mature myeloid and
lymphoid cells (from hematopoietic progenitors to mature
blood cells), their eﬀects on leukemic blasts are poorly
documented, and furthermore, their putative involvements
during leukemic diseases remain almost speculative. This
paper focuses on new results about lipid mediators and
human leukemic blast cells from acute myeloid (AML) and
acute lymphoid (ALL) patients. The vast majority of results
reported previously have been obtained with AML blasts
without maturation according to the classiﬁcation system of
the World Health Organization, thus corresponding to the
past AML M0−2 nomenclature.
2. PLA2,PLA 2 Receptors, andHuman
Leukemic Blasts
PLA2 catalyzes the hydrolysis of the sn-2 position of
membrane glycerophospholipids to liberate the eicosanoid
precursor AA (Figure 1)[ 3, 4]. Three distinct families
are documented: low molecular weight soluble forms of
PLA2 (sPLA2); Ca2+-dependent high molecular weight PLA2
(cytoplasmic PLA2,c P L A 2); cytoplasmic Ca2+-independent
high molecular weight PLA2 (iPLA2). In addition, the sPLA2
family is implicated in several biological processes such as
inﬂammation and host defence [3, 4]. Nine isoenzymes have
been identiﬁed. The cPLA2 family consists of four members,
with cPLA2-IVA being the central regulator of the stimulus-
coupledcellularAArelease[3,4].TheiPLA2 (PLA2-VI)plays
a major role in phospholipid remodelling. Freshly isolated
leukemic blasts from AML and ALL patients express mRNA
from four out of ﬁve cPLA2 (PLA2-IVA, PLA2-IVB, PLA2-
IVC, and PLA2-VI) and six out of nine sPLA2 (PLA2-IB,
PLA2-IIA, PLA2-IID, PLA2-V, PLA2-X, and PLA2-XII) and
that transcript levels exhibit wide variations as compared
to control blood mononuclear cells [5]. One of the most
notable ﬁndings is that AML and ALL blasts express high2 Journal of Oncology
amounts of PLA2-VI and PLA2-X. This could be extremely
signiﬁcant as these two enzymatic activities play a major
role in AA release for the generation of COX- and LOX-
derived lipid mediators. Thus, AML and ALL blasts have
the potential to express multiple isoforms of cPLA2 and
sPLA2 which could be of importance given the role of these
enzymes in inﬂammation, generation of lipid mediators,
anticoagulant activity, and bacterial infection. Biological
activities of PLA2 are attributed to their enzymatic capacity
tohydrolyzemembranephospholipids.However,inaddition
sPLA2 exerts various biological proinﬂammatory responses
through the binding to the cell surface PLA2 receptor (PLA2-
R) [6]. Of interest is the functional membrane PLA2-R
found on AML and ALL blasts strengthening a role for PLA2
signalling in these cells (Denizot and coll., in preparation).
The concept of anti-inﬂammation is currently evolving
with the discovery of endogenous inhibitory circuits, such
as the annexin (ANX) system, that are important in the
control of the host inﬂammatory response [7]. ANX-1
(also termed lipocortin) is a well-known cPLA2inhibitory
protein produced by and acting on several blood cell types
such as monocytes/macrophages and polymorphonuclear
leukocytes. The ANX-1 protein level is markedly elevated in
AML blasts [8], where ANX-1 is not only considered as an
anti-inﬂammatory and tumor suppressor molecule (through
its inhibiting cPLA2 activity) but also as one of the “eat-me”
signals on apoptotic cells to be recognised and ingested by
phagocytes [8]. It is, thus, tempting to speculate that PLA2-
R and ANX-1 might take an important place in the “yin”
and the “yang” of the inﬂammatory reaction occurring in
AML blasts. During the past decade, considerable research
hasbeendirectedtowardstheidentiﬁcationofnewbiological
targets for AML treatment. It is tempting to suggest that
PLA2-R antagonists might be one of them especially with
respecttotheemergingrolesforPLA2 enzymesincancer[9].
3. COX and HumanLeukemic Blasts
I nt h eC O Xp a t h w a y ,A Ai sc o n v e r t e dt oP G H 2 by COX-1
or COX-2 enzymes. PGH2 is subsequently metabolised to
generate diﬀerent prostanoids, depending on the enzymes
expressed in the cell [1]. The COX-1 isoform is typically
constitutively expressed unlike the inducible COX-2 one.
The growth-promoting properties of COX-2 in physiological
responses are diverted in malignancies [10]. COX-1 and
COX-2 transcripts are documented in AML and ALL blasts
[11], but only the COX-1 protein is found. Similarly COX-
1, but not the COX-2 protein, is detected in human primary
promyelocytic blasts during diﬀerentiation [12]. In fact, the
AML and ALL blasts can express the COX-2 protein in
response to lipopolysaccharide (LPS) but only in the subsets
of patients [13]. The ability of ALL blasts to express COX-
2 is consistent with its presence in stimulated normal B-cells
andinchroniclymphocyticleukaemia(CLL)B-cells[14,15].
The production of COX-2 in response to LPS by AML blasts
isconsistentwithdatareportingthatLPSisapotentinductor
of COX-2 in mature monocytes/macrophages [16] and that
stimulated HL-60 cells (an AML cell line with an M2/3
subtype) express COX-2 [17]. The heterogeneity in the LPS-
stimulated COX-2 expression by AML blasts is not linked
to a diﬀerent Toll-like receptor (TLR2 or TLR4) expression
[13] and remains an open question that requires further
evaluation.
4.PGE2,EPR ec e pt o rs,andH um an
Leukemic Blasts
Following the action of the COX pathway, PGH2 is sub-
sequently metabolized to generate diﬀerent prostanoids,
depending on the enzymes expressed in the cell. Prostanoids
include prostacyclin (PGI2), thromboxane A2 (TXA2), and
prostaglandin E2 (PGE2), synthesized by a PGI2 synthase, a
TXA synthase, and a PGE synthase, respectively [1]. Three
PGE synthase isoforms exist: inducible membrane-bound
PGE synthase-1 (mPGES-1), constitutive membrane-bound
PGE synthase-2, and cytosolic PGE synthase. In addition,
the ability of PGE2 to regulate the immune system has
been widely explored [18]. Data reporting the ability of
PGE2 to modulate several functions in mature blood cells
such as monocyte-macrophages, dendritic cells, and T and
B lymphocytes can be readily found. Human AML and
ALL blasts spontaneously release PGE2 [11], with PGE2
synthesis being inhibited by indomethacin. Transcripts for
mPGES-1 are detected in AML and ALL blasts suggesting
i t sr o l ei nP G E 2 synthesis (Denizot and coll., unpublished
results). PGE2 eﬀects are well known and are mediated
through interactions with four distinct membrane-bound
G-protein-coupled EP receptors: EP1,E P 2,E P 3,a n dE P 4
[18]. EP2 and EP4 are coupled to Gs and stimulate cAMP
production which leads to gene regulation. EP3 is coupled to
Gi and inhibit cAMP synthesis. EP1 is coupled to Gq/p,a n d
ligand binding induces intracellular calcium level variations.
Functional EP2 receptors are present on AML and ALL
blasts [19, 20]. In contrast to EP2 receptors, no functional
EP1,E P 3,a n dE P 4 receptors are found [20]. In view of the
potentially important role of PGE2 in processes of cancer
and leukocyte maturation and function, PGE2 eﬀects have
been investigated on blast cell proliferation and apoptosis.
PGE2 enhances the spontaneous and LPS-stimulated growth
of AML blasts without aﬀecting their apoptosis [11]. In
summary,AMLandALLblastssecretePGE2.Ar oleforPGE 2
asacompoundcontributingtoAMLcellproliferation(viaan
EP2 receptor-mediated pathway) can be hypothesized.
5. TXA2,PGI 2, andHuman Leukemic Blasts
TXA2 and PGI2 are two other potent COX metabolites.
TXA2 is produced abundantly by platelets upon exposure
to injured blood vessels and thus exhibits potent platelet-
aggregating and vessel-contracting activities. PGI2 is the
major COX-derived product of AA formed in the macrovas-
cular endothelium and is a potent inhibitor of platelet aggre-
gation activity and vessel vasodilatation activity [21]. AML
and ALL blasts express low levels of TX synthase transcripts
compared to normal blood mononuclear cells (Denizot and
coll., unpublished results) and additionally produce veryJournal of Oncology 3
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Figure 1: Simpliﬁed representation of the pathways involved in eicosanoid and platelet-activating factor formation and signal transduction.
Enzymatic activities and receptors are in rectangles and ovals, respectively. PLA2, phospholipase A2;C O X ,c y c l o o x y g e n a s e ;L O X ,l i p o x y g e -
nase; PGH2, prostaglandin H2;P G E 2, prostaglandin E2;P G I 2, prostacyclin; TXA2, thromboxane A2; HPETE, hydroperoxyeicosatetraenoic
acid; LTB4, leukotriene B4; HETE, hydroxyeicosatetraenoic acid; PAF, platelet-activating factor; PAFR, PAF receptor; EP1−4, subtype 1–4 of
the PGE2 receptor; IP, PGI2 receptor; TXA2R, TXA2 receptor; BLT1−2, subtype 1 and 2 of the LTB4 receptor.
low amounts of TXA2 in response to a calcium ionophore
stimulation [22]. HL-60 cells have also been shown to
release TXA2, but only after induction of diﬀerentiation
[23, 24]. PGI synthase transcripts are absent in AML and
ALL blasts, a result similar to that found in control blood
mononuclear cells (Denizot et coll., unpublished results).
In accordance with the absence of PGI transcripts in AML
and ALL blasts, calcium ionophore-stimulated blasts do not
release PGI2 (Denizot et coll., unpublished results). TXA2
and PGI2 act through membrane receptors (namely TXA2R
and IP for TXA2 and PGI2,r e s p . )[ 25, 26]. As to whether
AML and ALL blasts release TXA2 and PGI2, they express
levels of transcripts for TXA2R and IP equal or higher
than those found in control blood mononuclear cells [27].
TXA2R and IP receptors belong to the class of Gs-protein-
coupled receptors [25, 26]. Stimulation of leukemic blasts
with U-46619, the TXA2 receptor agonist U-46619, and PGI2
stimulate in a dose-dependant manner cAMP synthesis from
leukemic blasts showing the presence of functional TXA2R
a n dI Pr e c e p t o r s ,r e s p e c t i v e l y[ 27]. However, simulation of
leukemic blast with U-46619 and PGI2 has no eﬀect on
their growth and apoptosis rate. At the present time the
physiological meaning of functional TXA2Ra n dI Pr e c e p t o r s
on leukemic blasts remains an open question. In conclusion,
among the various COX-derived metabolites of AA only
PGE2 has, thus, a signiﬁcant eﬀect on the growth of AML
blast cells [11] ,a n dn o n eo ft h e ma ﬀect their apoptosis rate.
6. LOX and HumanLeukemic Blasts
The LOX pathway involves the conversion of AA to 5-,
12-, or 15-hydroperoxyeicosatetraenoic acids (HPETE) by4 Journal of Oncology
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Figure 2: Simpliﬁed representation of the relationships between lipid mediators and leukemic blasts. Leukemic cells express several cPLA2
and sPLA2. COX activities can metabolise AA into PGE2 and TXA2. LOX activities can metabolise AA into LTB4 and 12-HETE. Leukemic
cells can release PAF. Functional TXA2,I P ,E P 2, PAF, and PLA2 receptors are found on leukemic cells. BLT1 and BLT2 transcripts are detected
suggesting (?) LTB4 receptors. The immunoregulatory eﬀects of lipid mediators are currently speculative except for the role of PGE2 on AML
blast growth. Related references are in square brackets.
5-, 12-, or 15-LOX, respectively, HPETEs being rapidly
metabolized to 5-, 12, or 15-hydroxyeicosatetraenoic acids
(HETE). 5-HPETE could be dehydrated into leukotriene
A4 (LTA4), which was enzymatically hydrolyzed to LTB4
(Figure 1)[ 1]. The ability of LTB4, 12-HETE, and 15-
HETE to regulate important functions of the immune
system has been widely explored. These compounds activate
variousbloodcelltypesandstimulatetheirproinﬂammatory
cytokine productions [28–30], indicating an ability of LTB4,
12-HETE, and 15-HETE to augment and prolong tissue
inﬂammation. Leukemic blasts express 5-LOX, 12-LOX, and
15-LOX transcripts, their expression being in general lower
than in blood mononuclear cells from a healthy donor [22,
31, 32]. Leukemic blasts produce in vitro lower amounts
of LTB4 than healthy donors [22, 31, 33]. This reduced
capacity of AML blasts to produce LTB4 is located at the 5-
LOX level. Stimulated leukemic blasts produce 12-HETE but
not 15-HETE [22]. The various LOX-derived metabolites of
AA regulate a wide spectrum of cellular processes including
cell proliferation and apoptosis. 12-HETE and 15-HETE
stimulate the proliferation and diﬀerentiation of normal
CD34+ cells [34]. LTB4 induces proliferation and exerts an
antiapoptotic eﬀect on blood CD34+ cells [35]. However,
LTB4, 12-HETE, and 15 HETE have no eﬀect on the growth
and apoptosis rate of AML and ALL blasts in vitro [22].
As to whether receptors for 12-HETE and 15-HETE remain
to be molecularly identiﬁed, two G-protein-coupled seven
transmembrane domain receptors for LTB4 were identiﬁed:
BLT1andBLT2[36].AmountsofBLT1transcriptsaresimilar
in AML and ALL blasts as well as control blood mononuclear
cells, while amounts of BLT2 transcripts are markedly higher
[22]. At this time the physiological meaning (if any) of BLT1
and BLT2 transcripts in AML and ALL blasts remains an
open question. A similar question exists for the signiﬁcance
of LTB4- and 12-HETE-derived leukemic blasts. One might
suggest that these compounds could initiate, augment, andJournal of Oncology 5
prolong tissue inﬂammation and damages by aﬀecting the
cytokine network, but currently no studies have provided
evidences in support of this.
7.PAF, PAFR,and HumanLeukemic Blasts
PAF is a phospholipid mediator that sparks oﬀ aw i d e
range of immunoregulatory activities on blood cells such
as polymorphonuclear neutrophils, eosinophils, monocytes,
macrophages, and lymphocytes [2]. PAF is released in vitro
from several leukemic cell lines of B and T origin [37]a sw e l l
as from freshly isolated neoplastic cells of leukemic patients
[38]. However, in spite of experimental evidence reporting
its in vitro release from leukemic cells, no clinical studies
provide evidences to support this view in vivo. In contrast,
decreased levels of PAF are found in the blood of patients
with lymphoid and nonlymphoid hematologic malignancies
[39]. Blood PAF levels are regulated by an acetylhydrolase
activity (AHA, also named PLA2-VIIA) found in serum and
plasma. Plasma AHA is not altered in leukemic patients
[39] suggesting a lowered PAF production by leukemic cells
rather than an increased PAF catabolism. PAF acts through
membrane and nuclear PAF receptors (PAFR) that belong
to the G-protein-coupled family [40, 41]. As to whether
membrane PAFR is found on AML and ALL cells [42,
43], intracellular ones were detected [42]. Studies report
that mature monocytes, macrophages, polymorphonuclear
leukocytes, and B lymphocytes produce cAMP in response
to PAF [44, 45]. This is not the case for AML and ALL
blasts [46]. PAF modulates Ca2+ ﬂux through a Gq-protein-
mediated pathway [47]. The Gq proteins mediate their
eﬀects by activating phospholipase C and thus, generating
second messengers, inositol-1,4,5-triphosphate (IP3) and
diacylglycerol, thereby leading to the activation of protein
kinase C and the mobilisation of intracellular calcium. PAF
stimulates in a receptor-dependent process Ca2+ ﬂux from
AML and ALL blasts showing the presence of functional
PAFR [48] and highlighting that PAFR signals via the Gq
insteadoftheGi/Gsproteinpathways.Hence,theroleofPAF
in leukemic blasts still remains an open question. PAF has no
signiﬁcant eﬀect on growth and apoptosis rate in these cells
[49] suggesting that PAF is not an important modulator of
blast cell physiology. The lack of PAF eﬀect is linked to low
levels of PAFR in AML and ALL blasts compared to those
found in mature leukocytes [49]. Further, strengthening
this issue, the diﬀerentiation of HL-60 cells towards the
macrophage phenotype is associated with the induction of
PAFR gene expression. Thus, PAFR mRNA accumulation is
correlated to the induction and development of speciﬁc PAF
responsiveness [50].RecentlyWEB-2170, a PAFRantagonist,
has been reported to induce apoptosis in AML cells [51,
52]. In fact, WEB-2170 does not behave as a pure PAFR
but instead as an inverse agonist leading to a marked
cytoplasmic increase of PTEN proteins (PTEN is a pro-
tein/phosphoinositide phosphatase regulating the PI3K/Akt
signaling pathway). Consequently, these recent results [49,
51, 52] support the view that PAF has probably no signiﬁcant
role in the growth and apoptosis of leukemic blasts.
8. Conclusion
Data reporting our knowledge concerning the enzymatic
activities (such as PLA2, LOX, COX) implicated in lipid
mediator synthesis and their receptors on AML and ALL
blasts are schematised in Figure 2. Aberrant expression of
several PLA2 enzymes is common place in tumors derived
frommanydiﬀerentorgansites[9].Numerousstudiesreport
that altered AA metabolism in a solid tumor microenviron-
ment has a profound impact on the pathogenesis of tumor
development [1]. A multitude of biological activities of PAF
are evidenced both on the normal cell as well as on their
cancer counterpart [2]. There is evidence, however, that it is
not the case for leukemic blast cells. Among the various pro-
inﬂammatory lipid molecules so far tested (PAF, PGE2,P G I 2,
TXA2,L T B 4, 12-HETE, 15-HETE), none of them exhibit
any role on leukemic blast apoptosis despite the expression
of functional receptors (PAFR, EP2,I P ,T X A 2R). Among
the various compounds so far tested only PGE2 clearly
demonstrated a potential role in AML cell growth in vitro.
However, it is diﬃcult to compare the μM amounts of PGE2
used in most of the in vitro studies with the fM amounts of
PGE2 found in the blood at steady state conditions. Studies
showing the eﬀectsof continuous addition or infusion of low
doses of PGE2 (which seems to be a more relevant protocol
of stimulation to obtain information for the in vivo eﬀects
of PGE2) are extremely rare. Moreover, data obtained in
vivo and in vitro are sometimes discordant. In fact, there is
absolutely no evidence that PGE2 is implicated in the growth
of AML blasts in vivo. Thus, in conclusion the biological
eﬀects of eicosanoid and PAF are particularly important in
immunity and inﬂammation. Though their roles are well
known in numerous pathology and cancers, no such role is
currently known for leukemic blast growth.
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